Drug Trial Radar · NCT02111564
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Last checked: Nov 19, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12,024
Actual
Start
Jan 7, 2014
Primary completion
Mar 6, 2018
Study completion May 3, 2018
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Apr 11, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in high-risk, medically ill patients.
Conditions
- Heart Failure
- Respiratory Insufficiency
- Stroke Acute
- Infectious Diseases
- Rheumatic Diseases
Interventions
Rivaroxaban, 10 mgDrug
Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening greater than or equal to (\>=)50 mL/min will receive 10 mg rivaroxaban tablet with or without food.
Rivaroxaban, 7.5 mgDrug
Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from \>=30 to less than (\<)50 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.
PlaceboDrug
All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee (CEC)Time frame: Up to Day 45
- Event Rate Based on Time From Randomization to the First Occurrence of Major Bleeding Adjudicated by CECTime frame: From randomization to 2 days after the last dose (Day 45)
Locations
593 sites in 37 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mobile, Alabama
Site not named
Sheffield, Alabama
Site not named
Scottsdale, Arizona
Site not named
Fort Smith, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Beverly Hills, California
Site not named
Fullerton, California
Site not named
Los Angeles, California
Site not named
Newport Beach, California
Site not named
Orange, California
Site not named
Sacramento, California
Site not named
San Jose, California
Site not named
San Marino, California
Site not named
Santa Ana, California
Site not named
Colorado Springs, Colorado
Site not named
Bridgeport, Connecticut
Site not named
Danbury, Connecticut
Site not named
New Haven, Connecticut
Site not named
Waterbury, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Atlantis, Florida
Site not named
Bay Pines, Florida
Site not named
Bradenton, Florida
Site not named
Brandon, Florida
Site not named
Celebration, Florida
Site not named
Clearwater, Florida
Site not named
Daytona Beach, Florida
Site not named
Jacksonville, Florida
Site not named
Jacksonville Beach, Florida
Site not named
Largo, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Pensacola, Florida
Site not named
Saint Cloud, Florida
Site not named
Sebring, Florida
Site not named
Tampa, Florida
Site not named
Vero Beach, Florida
Site not named
Wellington, Florida
Showing 40 of 593 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.